What is Shenzhenlubris Pharmaceuticals Co Operating Cash Flow per Share?
Shenzhenlubris Pharmaceuticals Co's operating cash flow per share for the
three
months ended in Mar. 2024 was ¥0.21.
Shenzhenlubris Pharmaceuticals Co's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0.85.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -17.80% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -11.50% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 0.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Shenzhenlubris Pharmaceuticals Co's Operating Cash Flow per Share or its related term are showing as below:
SZSE:002294'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -17.8 Med: 26.6 Max: 106.3
Current: -17.8
During the past 13 years, Shenzhenlubris Pharmaceuticals Co's highest 3-Year average Operating Cash Flow per Share Growth Rate was 106.30% per year. The lowest was -17.80% per year. And the median was 26.60% per year.
SZSE:002294's 3-Year OCF Growth Rate is ranked worse than 74.96% of 687
companies
in the Medical Devices & Instruments industry
Industry Median: 2.6
vs SZSE:002294: -17.80
Shenzhenlubris Pharmaceuticals Co Operating Cash Flow per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Shenzhenlubris Pharmaceuticals Co Operating Cash Flow per Share Chart
Competitive Comparison of Shenzhenlubris Pharmaceuticals Co's Operating Cash Flow per Share
For the Medical Instruments & Supplies subindustry, Shenzhenlubris Pharmaceuticals Co's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhenlubris Pharmaceuticals Co's Price-to-Operating-Cash-Flow Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shenzhenlubris Pharmaceuticals Co's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Shenzhenlubris Pharmaceuticals Co's Price-to-Operating-Cash-Flow falls into.
Shenzhenlubris Pharmaceuticals Co Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.85
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhenlubris Pharmaceuticals Co Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Shenzhenlubris Pharmaceuticals Co's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Business Description
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, innovative biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other global countries and regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SZSE:002294 has been successfully added to your 